Evidence map›Paper›PMID 27745985›Full record

Trial reportInternational journal of radiation oncology, biology, physics2016

Multicenter Phase 2 Study of Cisplatin and 5-Fluorouracil With Concurrent Radiation Therapy as an Organ Preservation Approach in Patients With Squamous Cell Carcinoma of the Cervical Esophagus.

Sadamoto Zenda, Takashi Kojima, Ken Kato, Sachiko Izumi, Taijiro Ozawa, Naomi Kiyota, Chikatoshi Katada, Takahiro Tsushima, Yoshinori Ito, Tetsuo Akimoto and 3 more

Open access · hybridAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in International journal of radiation oncology, biology, physics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 2 pooled it
7.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 1 country.

Sadamoto ZendaDepartment of Radiation Oncology, National Cancer Center Hospital East, Chiba, Japan. Electronic address: szenda@east.ncc.go.jp.
Takashi KojimaDepartment of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.
Ken KatoDivision of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Sachiko IzumiDepartment of Radiation Oncology, Tokyo Women's Medical University, Tokyo, Japan.
Taijiro OzawaDepartment of Head and Neck Surgery, Aichi Cancer Center Hospital, Aichi, Japan.
Naomi KiyotaDepartment of Medical Oncology and Hematology, Kobe University Hospital, Hyogo, Japan.
Chikatoshi KatadaDepartment of Gastroenterology, Kitasato University School of Medicine, Sagamihara, Japan.
Takahiro TsushimaDepartment of Gastrointestinal Endoscopy and Oncology, Shizuoka Cancer Center Hospital, Shizuoka, Japan.
Yoshinori ItoDivision of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan.
Tetsuo AkimotoDepartment of Radiation Oncology, National Cancer Center Hospital East, Chiba, Japan.
Yasuhisa HasegawaDepartment of Head and Neck Surgery, Aichi Cancer Center Hospital, Aichi, Japan.
Miyuki KanamaruDepartment of Radiation Oncology, National Cancer Center Hospital East, Chiba, Japan.
Hiroyuki DaikoDepartment of Surgery, National Cancer Center Hospital East, Chiba, Japan.
National Cancer Center Hospital East · JPAichi Cancer Center · JPKitasato University · JPKobe University Hospital · JPShizuoka Cancer Center · JPTokyo National Hospital · JPTokyo Women's Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo clarify, in a multicenter, single-arm, phase 2 study (UMIN Clinical Trials Registry no. UMIN000001439), the clinical profile of chemoradiotherapy (CRT) for cervical esophageal cancer. PATIENTS AND

methodsPatients with operable cervical esophageal cancer, excluding candidates for endoscopic resection, were enrolled. Protocol treatment consisted of CRT and adjuvant chemotherapy (CT). First, patients received concurrent CRT with 5-fluorouracil (5-FU) plus cisplatin (CDDP). Chemotherapy consisted of 5-FU at 700 mg/m

resultsThirty patients were enrolled across 8 institutions in Japan, consisting of 26 men and 4 women with a median age of 64.5 years (range, 50-75 years). No grade 4 hematologic toxicity was seen in the CRT phase, and 1 grade 4 thrombocytopenia was seen in the CT phase. Grade 3 nonhematologic acute toxicities in the CRT phase were nausea (10%), mucositis (13.3%), and dysphagia (13.3%). No treatment-related death in either phase occurred. Overall complete response rate was 73%, and 3-year overall and laryngectomy-free survival were 66.5% and 52.5%, respectively. Regarding T4 disease, 3-year overall and laryngectomy-free survival were 58.3% and 38.5%, respectively.

conclusionsThis study, the first prospective study for cervical esophageal cancer, showed that CRT has sufficient efficacy and safety for use as an alternative to surgery for these patients.

Indexed as

AgedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Squamous CellCause of DeathChemoradiotherapyChemotherapy, AdjuvantCisplatinDeglutition DisordersDisease-Free SurvivalDrug Administration ScheduleEsophageal NeoplasmsFemaleFluorouracilHumansMaleMiddle AgedCisplatinFluorouracil

Identifiers

PMID27745985
OpenAlexW2517104933

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.